Drug
Insulin Glulisine
Insulin Glulisine: highest development phase Post-Market, developed by Sanofi. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Insulin Glulisine NCT00526513 | Post-Market | Diabetes Mellitus |
| insulin glulisine NCT00290927 | Phase 3 | Diabetes Mellitus, Type 2 |
Latest
No recent events.
Follow Insulin Glulisine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.